A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Inclusion Criteria:

Provide written informed consent
Women of child-bearing potential must have a negative pregnancy test

Multiple Myeloma:

Confirmed diagnosis of Multiple Myeloma with measurable disease, having been treated with at least two prior lines of therapy.

Lymphoma:

Confirmed diagnosis of Non-Hodgkin Lymphoma with measurable disease, having been treated with at least one anthracycline-based therapy, with relapse or progression since the last treatment received.

Exclusion Criteria:

Any of the following treatments, within the specified time frame, prior to the first dose of TAS4464:

Major surgery within 28 days
Radiation/chemotherapy within 21 days
Monoclonal antibodies within 28 days
Corticosteroid administration >20 mg/day of prednisone or equivalent within 14 days
Proteasome inhibitors within 14 days
Immunomodulatory agents within 7 days
Stem cell transplant within 3 months
Current immunosuppressive treatment for graft versus host disease
Current use of an investigational agent
Active graft versus host disease
Known serious illness or medical condition
Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class
Pregnant or breast-feeding female